Work

Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP

Year: 2018

Type: article

Abstract: The peripheral T-cell lymphomas remain a therapeutic challenge because these aggressive cancers are both rare and extremely diverse. In fact, the most common peripheral T-cell lymphoma in Europe and North America is unspecified and remains a diagnosis of exclusion. CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) emerged as the standard of care in the treatment of aggressive non-Hodgkin lymphomas in the 1990s when the distinction between peripheral T-cell lymphoma and aggressive B-cell-derived non-Hodgkin lymphoma became apparent.

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(18)30047-4

Author: Ryan A Wilcox

Institutions: University of Michigan, U-M Rogel Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,280